A surge in multi-billion dollar deals, led by Fifth Third's $11B acquisition of Comerica, signals a new wave of consolidation.
Building materials giant cites stronger-than-expected sales and profitability, signaling modest improvement in its key siding market.
Zepzelca, in combination with Roche's Tecentriq, approved as first-line maintenance treatment for extensive-stage small cell lung cancer.
Regulator signals openness to an accelerated approval pathway for LX2006, a promising treatment for Friedreich's Ataxia cardiomyopathy.
FDA grants Breakthrough Therapy Designation for the company's treatment of Sanfilippo Syndrome, a rare neurodegenerative disorder.
FDA grants Breakthrough Therapy Designation to the company's drug for a rare, fatal pediatric disorder, paving the way for accelerated review and potential approval.
Shares surged in after-hours trading after the company revealed positive results for its lead drug candidate, Telomir-1, in age-related studies.
Nimacimab monotherapy misses primary weight-loss endpoint, though combination with semaglutide shows promise, raising questions for the drug's future.